AI English summary of an SEC filing — figures as filed
Eli Lilly LLYThe company said revenue rose for the 3- and 9-month periods ended September 30, 2026, driven mainly by higher volume, which was partly offset by lower realized prices. It said the higher volume and lower prices were mainly driven by Mounjaro and Zepbound.
Key points
AI summaryThe company said revenue rose for the 3- and 9-month periods ended September 30, 2026, driven mainly by higher volume, which was partly offset by lower realized prices. It said the higher volume and lower prices were mainly driven by Mounjaro and Zepbound.
Lilly said the main drivers of higher net income and earnings per share for the 3- and 9-month periods were higher gross margin. It said higher acquired IPR&D charges, research and development expenses, and marketing, selling, and administrative expenses partly offset those gains.
The company said Mounjaro revenue rose 41% and 47% in the U.S. for the 3- and 9-month periods, respectively, and 93% and 153% outside the U.S. It said the increase outside the U.S. was mainly driven by higher volume, partly offset by lower realized prices from the inclusion of Mounjaro on China's NRDL.
The company said cash and cash equivalents stood at $4.9 billion as of September 30, 2026, down from $7.3 billion as of December 31, 2025. It said total debt was $49.5 billion at that date, an increase of $7.0 billion, and that it paid $18.2 billion for business development activity over the 9 months.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Revenue Growth and the Impact of Mounjaro and Zepbound
The company said revenue rose for the 3- and 9-month periods ended September 30, 2026, driven mainly by higher volume, which was partly offset by lower realized prices. It said the higher volume and lower prices were mainly driven by Mounjaro and Zepbound.
Source · Based on the MD&A text of the filing
Net Income and Changes in Expense Items
Lilly said the main drivers of higher net income and earnings per share for the 3- and 9-month periods were higher gross margin. It said higher acquired IPR&D charges, research and development expenses, and marketing, selling, and administrative expenses partly offset those gains.
Source · Based on the MD&A text of the filing
Mounjaro Revenue Changes in the U.S. and Outside the U.S.
The company said Mounjaro revenue rose 41% and 47% in the U.S. for the 3- and 9-month periods, respectively, and 93% and 153% outside the U.S. It said the increase outside the U.S. was mainly driven by higher volume, partly offset by lower realized prices from the inclusion of Mounjaro on China's NRDL.
Source · Based on the MD&A text of the filing
Changes in Cash and Debt Balances
The company said cash and cash equivalents stood at $4.9 billion as of September 30, 2026, down from $7.3 billion as of December 31, 2025. It said total debt was $49.5 billion at that date, an increase of $7.0 billion, and that it paid $18.2 billion for business development activity over the 9 months.
Source · Based on the MD&A text of the filing
Structured SEC financial data for this filing is not available yet. Please check the figures in the SEC filing.
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…